Clinical Benefit of Second-Line Palliative Chemotherapy in Advanced Soft-Tissue Sarcoma

Table 2

Second-line chemotherapy regimens and disease control rate.

Chemotherapy	Single agent doxorubicin					62 (16.4%)
	Single agent ifosfamide					123 (32.5%)
	Other Single agent					106 (28.0%)
	Doxorubicin/ifosfamide					21 (5.5%)
	Other combination					32 (8.4%)
	Phase I trial					35 (9.2%)
Number of Cycles	1	2	3	4	5	6	>6
	72	111	35	49	16	68	28
Response	CR					8 (2.1%)
	PR					20 (5.3%)
	SD					76 (20.1%)
	PD					266 (70.2%)
	NA					9 (2.4%)
Disease control rate	CR/PR/SD >6 months					86 (23.2%)
	Non responder					284 (76.8%)

CR: complete response, PR: partial response, SD: stable disease, PD: progressive disease, NA: not assessable.